Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.12 SEK | -3.23% |
|
+26.32% | +19.52% |
15/07 | Cyxone Sets Clinical Development Focus for Arthritis, Multiple Sclerosis Drugs | MT |
15/07 | Cyxone AB Provides an Update on its Research and Development Program | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.52% | 2.53M | |
+6.00% | 72.01B | |
+30.80% | 10.39B | |
+41.28% | 5.26B | |
-18.53% | 4.64B | |
+18.24% | 3.7B | |
+26.86% | 2.3B | |
-39.52% | 1.8B | |
-45.54% | 1.7B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- CYXO Stock
- News Cyxone AB
- Cyxone Sets Clinical Development Focus for Arthritis, Multiple Sclerosis Drugs